The evolving science of Clesrovimab: pharmacological insights and clinical implications

Clesrovimab (MK-1654) is a next-generation monoclonal antibody (mAb) engineered for the prophylaxis of Respiratory Syncytial Virus (RSV or HRSV), a major etiological agent of lower respiratory tract infections in newborns, the elderly, and immunocompromised individuals. Having received regulatory approval in the United States and the United Arab Emirates in 2025, and currently under review in additional global markets, Clesrovimab has demonstrated robust immunoprophylactic efficacy in clinical trials. A single-dose administration provides durable protection, a significant reduction in RSV-associated infections and hospitalizations versus placebo, and a favorable safety profile with a lower incidence of adverse events (AEs) compared with existing standard-of-care interventions. This narrative review summarizes Clesrovimab’s molecular characteristics and clinical development, outlining key improvements observed in late-phase trials. Relevant data were identified through a literature search of PubMed, Scopus, and ClinicalTrials.gov (2018–2025) using the keywords “Clesrovimab,” “MK-1654,” and “respiratory syncytial virus”. A comparative analysis is presented with currently approved RSV-targeting mAbs, such as Palivizumab and Nirsevimab. The aim is to highlight Clesrovimab’s potential as a novel preventive strategy against RSV infection, emphasizing its enhanced binding affinity for the viral fusion (F) protein, superior biodistribution within the respiratory tract, and capacity to provide more effective and sustained protection. These features support its promising role in reducing RSV-related morbidity and mortality among high-risk populations.

1. Phuah JY, Maas BM, Tang A, et al. Quantification of clesrovimab, an investigational, half-life extended, anti-respiratory syncytial virus protein F human monoclonal antibody in the nasal epithelial lining fluid of healthy adults. Biomed Pharmacother 2023;169:11585. DOI: https://doi.org/10.1016/j.biopha.2023.115851

2. Vandini S, Biagi C, Lanari M. Respiratory syncytial virus: The influence of serotype and genotype variability on clinical course of infection. Int J Mol Sci 2017;18:1717. DOI: https://doi.org/10.3390/ijms18081717

3. Odumade OA, van Haren SD, Angelidou A. Implications of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic on the epidemiology of pediatric respiratory syncytial virus infection. Clin Infect Dis 2022;75:S130-5. DOI: https://doi.org/10.1093/cid/ciac373

4. Messina A, Germano C, Avellis V, et al. New strategies for the prevention of respiratory syncytial virus (RSV). Early Hum Dev 2022;174:105666. DOI: https://doi.org/10.1016/j.earlhumdev.2022.105666

5. Li Y, Wang X, Blau DM, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: A systematic analysis. Lancet 2022;399:2047-64. DOI: https://doi.org/10.1016/S0140-6736(22)00478-0

6. Battles MB, McLellan JS. Respiratory syncytial virus entry and how to block it. Nat Rev Microbiol 2019;17:233-45. DOI: https://doi.org/10.1038/s41579-019-0149-x

7. Babawale PI, Martínez-Espinoza I, Mitchell AM, et al. Preventing RSV infection in children: Current passive immunizations and vaccine development. Pathogens 2025;14:104. DOI: https://doi.org/10.3390/pathogens14020104

8. Nuttens C, Moyersoen J, Curcio D, et al. Differences between RSV A and RSV B subgroups and implications for pharmaceutical preventive measures. Infect Dis Ther 2024;13:1725-42. DOI: https://doi.org/10.1007/s40121-024-01012-2

9. Tang A, Chen Z, Cox KS, et al. A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein. Nat Commun 2019;10:4153. DOI: https://doi.org/10.1038/s41467-019-12137-1

10. Sinha A. Clesrovimab (MK-1654): Pediatric clinical program. Presentation to the Advisory Committee on Immunization Practices. 2024 Oct 23; Rahway, NJ, USA. Merck & Co., Inc.

11. Fridman A, Love-Gregory L, Railkar R, et al. Clesrovimab binding site conservation on the RSV F protein: An evaluation of RSV molecular sequencing data from 2019-2023 and GenBank sequence analysis. Open Forum Infect Dis 2025;12:ofae631. DOI: https://doi.org/10.1093/ofid/ofae631.2486

12. Zhu Q, McLellan JS, Kallewaard NL, et al. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Sci Transl Med 2017;9:eaaj1928. DOI: https://doi.org/10.1126/scitranslmed.aaj1928

13. Aliprantis AO, Wolford D, Caro L, et al. A Phase 1 randomized, double-blind, placebo-controlled trial to assess the safety, tolerability, and pharmacokinetics of a respiratory syncytial virus neutralizing monoclonal antibody MK-1654 in healthy adults. Clin Pharmacol Drug Dev 2021;10:556-66. DOI: https://doi.org/10.1002/cpdd.883

14. Orito Y, Otani N, Matsumoto Y, et al. A phase I study to evaluate safety, pharmacokinetics, and pharmacodynamics of respiratory syncytial virus neutralizing monoclonal antibody MK-1654 in healthy Japanese adults. Clin Transl Sci 2022;15:1753-63. DOI: https://doi.org/10.1111/cts.13290

15. Madhi SA, Simões EAF, Acevedo A, et al. A Phase 1b/2a trial of a half-life extended respiratory syncytial virus neutralizing antibody, clesrovimab, in healthy preterm and full-term infants. J Infect Dis 2025;231:478-87. DOI: https://doi.org/10.1093/infdis/jiae581

16. Maas B, Aliprantis A, Wolford D, et al. Rsv monoclonal antibody (mk-1654) phase 1 pharmacokinetics (pk) in healthy adults and population pk modeling to support pediatric development. Open Forum Infect Dis 2018;5:S424-5. DOI: https://doi.org/10.1093/ofid/ofy210.1215

17. Merck Sharp & Dohme LLC. Efficacy and safety of Clesrovimab (MK-1654) in infants (MK-1654-004). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); accessed: 2025 Apr 7.

18. Zar HJ, Bont LJ, Manzoni P, et al. Clesrovimab in infants and children at increased risk for severe RSV disease. N Engl J Med 2025;393:1343-5. DOI: https://doi.org/10.1056/NEJMc2506107

19. Merck Sharp & Dohme LLC. Clesrovimab (MK-1654) in infants and children at increased risk for severe respiratory syncytial virus (RSV) disease (MK-1654-007). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); accessed 2025 Apr 7.

20. Sinha A, Railkar RA, Castagnini L, et al. Evaluation of a monoclonal antibody against respiratory syncytial virus, clesrovimab, in infants and children: Comprehensive rationale and study design for the late-stage clinical trials. Contemp Clin Trials 2025;157:107995. DOI: https://doi.org/10.1016/j.cct.2025.107995

21. Wu H, Pfarr DS, Losonsky GA, et al. Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab. Curr Top Microbiol Immunol 2008;317:103-23. DOI: https://doi.org/10.1007/978-3-540-72146-8_4

22. European Medicines Agency. Synagis, INN-palivizumab: Summary of product characteristics. 2018 May 8. Accessed 2025 Apr 7.

23. Li Q, Li H, Li Z, et al. Vaccine and therapeutic agents against the respiratory syncytial virus: Resolved and unresolved issue. MedComm 2024;5:e70016. DOI: https://doi.org/10.1002/mco2.70016

24. Garegnani L, Styrmisdóttir L, Roson Rodriguez P, et al. Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children. Cochrane Database Syst Rev 2021;11:CD013757.

25. Blanken MO, Rovers MM, Molenaar JM, et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med 2013;368:1791-9. DOI: https://doi.org/10.1056/NEJMoa1211917

26. Nobili C, Peroglio S, Riccò M, Manzoni P. Strategie di contrasto verso il Virus Respiratorio Sinciziale: profilassi universale con nuovi Anticorpi Monoclonali e ulteriori opzioni innovative [Tackling respiratory syncytial virus: Universal prophylaxis with new monoclonal antibodies and further innovative strategies]. Penumologia Pediatrica 2024;25:8-12.

27. Mazur NI, Löwensteyn YN, Terstappen J, et al. Daily intranasal palivizumab to prevent respiratory syncytial virus infection in healthy preterm infants: A phase 1/2b randomized placebo-controlled trial. Lancet Respir Med 2025;3:39-52.

28. Sevendal ATK, Hurley S, Bartlett AW, et al. A systematic review of the efficacy and safety of RSV-specific monoclonal antibodies and antivirals in development. Rev Med Virol 2024;34:e2576. DOI: https://doi.org/10.1002/rmv.2576

29. European Medicines Agency. Beyfortus, INN-nirsevimab: Summary of product characteristics. 2023 Dec 1. Accessed 2025 Apr 9.

30. ClinicalTrials.gov. A study to evaluate the safety and efficacy of MEDI8897 for the prevention of medically attended RSV LRTI in healthy preterm infants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2023. Accessed 2025 Apr 9.

31. Griffin MP, Yuan Y, Takas T, et al. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med 2020;383:415-25. DOI: https://doi.org/10.1056/NEJMoa1913556

32. Ahani B, Tuffy KM, Aksyuk AA, et al. Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials. Nat Commun 2023;14:4347. DOI: https://doi.org/10.1038/s41467-023-40057-8

33. ClinicalTrials.gov. A study to evaluate the safety and efficacy of MEDI8897 for the prevention of medically attended lower respiratory tract infection due to respiratory syncytial virus in healthy late preterm and term infants (MELODY). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2023. Accessed 2025 Apr 9.

34. Domachowske J, Madhi SA, Simões EAF, et al. Safety of nirsevimab for RSV in infants with heart or lung disease or prematurity. N Engl J Med 2022;386:892-4. DOI: https://doi.org/10.1056/NEJMc2112186

35. Simões EAF, Madhi SA, Muller WJ, et al. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: A pooled analysis of randomised controlled trials. Lancet Child Adolesc Health 2023;7:180-9. DOI: https://doi.org/10.1016/S2352-4642(22)00321-2

36. Domachowske JB. New and emerging passive immunization strategies for the prevention of RSV infection during infancy. J Pediatric Infect Dis Soc 2024;13:S115-24. DOI: https://doi.org/10.1093/jpids/piae030

37. Thambi N, Phuah JY, Staupe RP, et al. Development of high-titer antidrug antibodies in a phase 1b/2a infant clesrovimab trial are associated with RSV exposure beyond day 150. J Infect Dis 2025;231:e488-96. DOI: https://doi.org/10.1093/infdis/jiae582

38. Boswell CA, Tesar DB, Mukhyala K, Theil FP, Fielder PJ, Khawli LA. Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem 2010;21:2153–63. DOI: https://doi.org/10.1021/bc100261d

39. Maas BM, Lommerse J, Plock N, et al. Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis. EBioMedicine 2021;73:103651. DOI: https://doi.org/10.1016/j.ebiom.2021.103651

40. Garegnani L, Styrmisdóttir L, Roson Rodriguez P, et al. Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children. Cochrane Database Syst Rev 2021;11:CD013757. DOI: https://doi.org/10.1002/14651858.CD013757.pub2

41. Liu L. Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins. Protein Cell 2018;9:15-32. DOI: https://doi.org/10.1007/s13238-017-0408-4

42. Fernández P, Trenholme A, Abarca K, et al. A phase 2, randomized, double-blind safety and pharmacokinetic assessment of Respiratory Syncytial Virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season. BMC Pediatr 2010;10:38. DOI: https://doi.org/10.1186/1471-2431-10-38

43. Null DM, Connor EM, Palivizumab Study Group. Evaluation of immunogenicity and safety in children receiving palivizumab for a second RSV season. Pediatr Res 1999;45:170. DOI: https://doi.org/10.1203/00006450-199904020-01010